NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
AstraZeneca
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Sellas Life Sciences Group
Merck Sharp & Dohme LLC
Advaxis, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Gilead Sciences
PharmaMar
Takeda
Pfizer
University of Kansas Medical Center
MEI Pharma, Inc.
Amgen
Roswell Park Cancer Institute
Amgen
Fox Chase Cancer Center
INSYS Therapeutics Inc